Rituximab treatment of idiopathic membranous nephropathy

Fernando Custodio Fervenza, Fernando G Cosio, S. B. Erickson, Ulrich Specks, A. M. Herzenberg, J. J. Dillon, N. Leung, I. M. Cohen, D. N. Wochos, E. Bergstralh, M. Hladunewich, D. C. Cattran

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Idiopathic membranous nephropathy is a common cause of nephrotic syndrome whose pathogenesis may involve B-cell functions. Rituximab is a monoclonal antibody that binds to the CD20 antigen on B cells thereby deleting them. We conducted an open-label pilot trial of rituximab treatment in 15 severely nephrotic patients with proteinuria refractory to angiotensin-converting enzyme inhibition and/or receptor blockade but with adequately controlled blood pressure. Rituximab was given 2 weeks apart and, at 6 months, patients who remained proteinuric but had recovered B-cell counts were given a second course of treatment. Proteinuria was significantly decreased by about half at 12 months. Of the 14 patients who completed follow-up, full remission was achieved in two and partial remission in six patients based upon the degree of proteinuria. Side effects were minor; however, we found no relationship between the response and number of B cells in the blood, CD20 cells in the kidney biopsy, degree of tubulointerstitial fibrosis, starting proteinuria or creatinine values. Rituximab appears effective in reducing proteinuria in some patients with idiopathic membranous nephropathy but prospective identification of responsive patients was not possible.

Original languageEnglish (US)
Pages (from-to)117-125
Number of pages9
JournalKidney International
Volume73
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Membranous Glomerulonephritis
Proteinuria
B-Lymphocytes
Therapeutics
CD20 Antigens
Nephrotic Syndrome
Peptidyl-Dipeptidase A
Rituximab
Blood Cells
Creatinine
Fibrosis
Cell Count
Monoclonal Antibodies
Blood Pressure
Kidney
Biopsy

Keywords

  • Membranous nephropathy
  • Nephrotic syndrome
  • Pharmacodynamics, HACA
  • Pharmacokinetics
  • Rituximab

ASJC Scopus subject areas

  • Nephrology

Cite this

Fervenza, F. C., Cosio, F. G., Erickson, S. B., Specks, U., Herzenberg, A. M., Dillon, J. J., ... Cattran, D. C. (2008). Rituximab treatment of idiopathic membranous nephropathy. Kidney International, 73(1), 117-125. https://doi.org/10.1038/sj.ki.5002628

Rituximab treatment of idiopathic membranous nephropathy. / Fervenza, Fernando Custodio; Cosio, Fernando G; Erickson, S. B.; Specks, Ulrich; Herzenberg, A. M.; Dillon, J. J.; Leung, N.; Cohen, I. M.; Wochos, D. N.; Bergstralh, E.; Hladunewich, M.; Cattran, D. C.

In: Kidney International, Vol. 73, No. 1, 01.2008, p. 117-125.

Research output: Contribution to journalArticle

Fervenza, FC, Cosio, FG, Erickson, SB, Specks, U, Herzenberg, AM, Dillon, JJ, Leung, N, Cohen, IM, Wochos, DN, Bergstralh, E, Hladunewich, M & Cattran, DC 2008, 'Rituximab treatment of idiopathic membranous nephropathy', Kidney International, vol. 73, no. 1, pp. 117-125. https://doi.org/10.1038/sj.ki.5002628
Fervenza, Fernando Custodio ; Cosio, Fernando G ; Erickson, S. B. ; Specks, Ulrich ; Herzenberg, A. M. ; Dillon, J. J. ; Leung, N. ; Cohen, I. M. ; Wochos, D. N. ; Bergstralh, E. ; Hladunewich, M. ; Cattran, D. C. / Rituximab treatment of idiopathic membranous nephropathy. In: Kidney International. 2008 ; Vol. 73, No. 1. pp. 117-125.
@article{192131fd039a45cf97c6c1a75d4adcc1,
title = "Rituximab treatment of idiopathic membranous nephropathy",
abstract = "Idiopathic membranous nephropathy is a common cause of nephrotic syndrome whose pathogenesis may involve B-cell functions. Rituximab is a monoclonal antibody that binds to the CD20 antigen on B cells thereby deleting them. We conducted an open-label pilot trial of rituximab treatment in 15 severely nephrotic patients with proteinuria refractory to angiotensin-converting enzyme inhibition and/or receptor blockade but with adequately controlled blood pressure. Rituximab was given 2 weeks apart and, at 6 months, patients who remained proteinuric but had recovered B-cell counts were given a second course of treatment. Proteinuria was significantly decreased by about half at 12 months. Of the 14 patients who completed follow-up, full remission was achieved in two and partial remission in six patients based upon the degree of proteinuria. Side effects were minor; however, we found no relationship between the response and number of B cells in the blood, CD20 cells in the kidney biopsy, degree of tubulointerstitial fibrosis, starting proteinuria or creatinine values. Rituximab appears effective in reducing proteinuria in some patients with idiopathic membranous nephropathy but prospective identification of responsive patients was not possible.",
keywords = "Membranous nephropathy, Nephrotic syndrome, Pharmacodynamics, HACA, Pharmacokinetics, Rituximab",
author = "Fervenza, {Fernando Custodio} and Cosio, {Fernando G} and Erickson, {S. B.} and Ulrich Specks and Herzenberg, {A. M.} and Dillon, {J. J.} and N. Leung and Cohen, {I. M.} and Wochos, {D. N.} and E. Bergstralh and M. Hladunewich and Cattran, {D. C.}",
year = "2008",
month = "1",
doi = "10.1038/sj.ki.5002628",
language = "English (US)",
volume = "73",
pages = "117--125",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Rituximab treatment of idiopathic membranous nephropathy

AU - Fervenza, Fernando Custodio

AU - Cosio, Fernando G

AU - Erickson, S. B.

AU - Specks, Ulrich

AU - Herzenberg, A. M.

AU - Dillon, J. J.

AU - Leung, N.

AU - Cohen, I. M.

AU - Wochos, D. N.

AU - Bergstralh, E.

AU - Hladunewich, M.

AU - Cattran, D. C.

PY - 2008/1

Y1 - 2008/1

N2 - Idiopathic membranous nephropathy is a common cause of nephrotic syndrome whose pathogenesis may involve B-cell functions. Rituximab is a monoclonal antibody that binds to the CD20 antigen on B cells thereby deleting them. We conducted an open-label pilot trial of rituximab treatment in 15 severely nephrotic patients with proteinuria refractory to angiotensin-converting enzyme inhibition and/or receptor blockade but with adequately controlled blood pressure. Rituximab was given 2 weeks apart and, at 6 months, patients who remained proteinuric but had recovered B-cell counts were given a second course of treatment. Proteinuria was significantly decreased by about half at 12 months. Of the 14 patients who completed follow-up, full remission was achieved in two and partial remission in six patients based upon the degree of proteinuria. Side effects were minor; however, we found no relationship between the response and number of B cells in the blood, CD20 cells in the kidney biopsy, degree of tubulointerstitial fibrosis, starting proteinuria or creatinine values. Rituximab appears effective in reducing proteinuria in some patients with idiopathic membranous nephropathy but prospective identification of responsive patients was not possible.

AB - Idiopathic membranous nephropathy is a common cause of nephrotic syndrome whose pathogenesis may involve B-cell functions. Rituximab is a monoclonal antibody that binds to the CD20 antigen on B cells thereby deleting them. We conducted an open-label pilot trial of rituximab treatment in 15 severely nephrotic patients with proteinuria refractory to angiotensin-converting enzyme inhibition and/or receptor blockade but with adequately controlled blood pressure. Rituximab was given 2 weeks apart and, at 6 months, patients who remained proteinuric but had recovered B-cell counts were given a second course of treatment. Proteinuria was significantly decreased by about half at 12 months. Of the 14 patients who completed follow-up, full remission was achieved in two and partial remission in six patients based upon the degree of proteinuria. Side effects were minor; however, we found no relationship between the response and number of B cells in the blood, CD20 cells in the kidney biopsy, degree of tubulointerstitial fibrosis, starting proteinuria or creatinine values. Rituximab appears effective in reducing proteinuria in some patients with idiopathic membranous nephropathy but prospective identification of responsive patients was not possible.

KW - Membranous nephropathy

KW - Nephrotic syndrome

KW - Pharmacodynamics, HACA

KW - Pharmacokinetics

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=37248999499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37248999499&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5002628

DO - 10.1038/sj.ki.5002628

M3 - Article

C2 - 17943078

AN - SCOPUS:37248999499

VL - 73

SP - 117

EP - 125

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 1

ER -